An observational study in Peri-implantitis, sponsored by Bioteck S.p.A.. Recruiting at 1 site in Spain. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Bioteck S.p.A. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Peri-Implantitis with a site in Spain — 16 open to participants now, 19 under way, none of them phase 3. Peri-Implantitis · Spain.
Among the 50 studies in Peri-Implantitis with a site in Spain, this one is the 16th largest by planned enrollment of the 22 observational ones that give a count, is one of 4 that started in 2025, is one of 22 observational ones, reaches primary completion later than 15 of the 18 other live ones, and was the 47th registered.
324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.
Browse Peri-Implantitis studies →16 of the 50 studies in Peri-Implantitis with a site in Spain are open now. Recruiting first, the newest first:
Arrow Development · Sites in Spain
Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain · Sites in Spain
Ages up to 90 · Healthy volunteers
Universitat Internacional de Catalunya · Sites in Spain
Ages 18+ · Healthy volunteers
Universitat Internacional de Catalunya · Sites in Spain
Ages 18+ · Healthy volunteers
Universidad de Murcia · Sites in Spain
Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 56 is below the median of 84 across 122 observational studies indexed under Peri-Implantitis.
Median enrollment 37 across the 27 interventional studies, 117 across the 22 observational. Of the 26 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 50 have an industry lead sponsor. The 10 most frequent:
Bioteck S.p.A. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Bioteck S.p.A. has 1 study filed under Peri-Implantitis — fewer than ten, so there is no comparison to draw.
5 of the studies in Peri-Implantitis with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07557459Arrow DevelopmentAccess to Probing and Peri-implant Diseases | 2027-05 |
| NCT07638969Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, SpainOccurrence of Peri-Implant Complications: A Multifactorial Cross-Sectional Study | 2027-07-01 |
| NCT07590037University of BarcelonaComparison of Anesthetic Efficacy and Safety Between Inferior Alveolar Nerve Block and the Infiltrative Technique for the Treatment of Peri-implant Diseases in Posterior Mandibular Implants | 2027-09 |
| NCT07694323University of BarcelonaPatient Perspectives Throughout Peri-Implantitis Treatment | 2027-09-03 |
| NCT07680491Bioteck S.p.A.Non-surgical Treatment of Peri-implant Pockets With H42 | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 50 studies in Peri-Implantitis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, observational study evaluates the efficacy and safety of H42 non-surgical treatment for peri-implant pockets. The trial involves 56 patients, with 28 subjects receiving the H42 treatment and 28 acting as a control group to monitor soft tissue healing and bone level changes.
Clinical outcomes focus on Pocket Probing Depth (PPD) and Silness and Löe Plaque Index (PI) measured at baseline, 1 month, and 3 months. Gingival inflammation, pain intensity on a 0-10 NRS scale, and absence of infection are monitored at baseline, 7, 14, and 21 days, and at 1 and 3 months. Additionally, a five-point tissue assessment evaluates color, suppuration, granulation tissue, bleeding, and incision margins. Radiographic analysis at baseline and 3 months uses standardized periapical x-rays to measure bone level, intra-bony defect height, width, and angulation. Safety is assessed through the continuous registration of adverse events.
Adult patients diagnosed with peri-implantitis and treated at the Department of Stomatology, Faculty of Dentistry, University of Seville, Spain. Participants are recruited from patients seeking care at the university dental clinic and are allocated to the study groups according to the study protocol and predefined inclusion and exclusion criteria. The study evaluates the adjunctive use of H42 hydrogel in the non-surgical treatment of peri-implantitis using a case-control design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
28 patients treated with ultrasonic treatment and manual curettes + H42®
28 patients only with ultrasonic treatment and manual curettes
Pocket Probing Depth (PPD)
The distance measured from the base of the pocket to the most apical point on the gingival margin, and it will be measured with an electronic Florida probe at controlled pressure
Time frame: At 1 month and 3 months in comparison with the baseline value
Plaque Index (PI)
For each tooth, the four-point scale Silness and Löe Plaque Index is used (Score 0: Excellent; 3: poor)
Time frame: At 1 month and 3 months in comparison with the baseline
Degree of inflammation
Not inflamed, mild inflamed, Moderately inflamed, Very inflamed
Time frame: Baseline and 7 days, at 14 days, at 21 days, at 1 month and 3 months of follow-up
NRS scale
Numeric Rating Scale is a simple, reliable tool used to measure pain intensity on a scale from 0 to 10 (0: no pain; 10: maximum pain)
Time frame: Baseline and 7 days, at 14 days, at 21 days, at 1 month and 3 months of follow-up
Absence of infection
Clinical evaluation to assess the absence of infection, specifically defined as the absence of suppuration (pus formation), at the treated site as evaluated by the Investigator.
Time frame: Baseline and 7 days, at 14 days, at 21 days, at 1 month and 3 months of follow-up
Tissue assessment
Color, suppuration, granulation tissue, bleeding on palpation and incision margins on a five-point scale: 1 is very poor, 2 is poor, 3 is good, 4 is very good, and 5 is excellent
Time frame: Baseline and 7 days, at 14 days, at 21 days, at 1 month and 3 months of follow-up
Radiographic image (x-ray)
Periapical radiographs were taken using the parallel long cone technique using a customized film-holder device and a bite block. - Bone level (BL): distance (mm) between the implant shoulder and the base of the defect.
Time frame: Baseline and 3 months follow-up
Plan to share: No
Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.
Of 35 observational studies under Peri-Implantitis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 77. This study's planned 21 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.